0.25Open0.25Pre Close0 Volume157 Open Interest15.00Strike Price0.00Turnover0.00%IV151.65%PremiumOct 18, 2024Expiry Date0.00Intrinsic Value100Multiplier-2DDays to Expiry0.25Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma24.24Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Candel Therapeutics Stock Discussion
Candel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual Meeting
Candel Therapeutics (Nasdaq: CADL), a clinical-stage biopharmaceutical company developing multimodal biological immunotherapies for cancer, announced its upcoming presentation at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting. The event will take place from November 6-10, 2024, in Houston, Texas, and virtually.
The c...
Larger Image: tradingview.com...
$Candel Therapeutics (CADL.US)$
No comment yet